Cargando…

Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2

There are a number of uncertainties regarding plasma protein binding and blood distribution of the active drugs favipiravir (FAVI), molnupiravir (MOLNU) and imatinib (IMA), which were recently proposed as therapeutics for the treatment of COVID-19 disease. Therefore, proton dissociation processes, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dömötör, Orsolya, Enyedy, Éva A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917862/ https://www.ncbi.nlm.nih.gov/pubmed/36769193 http://dx.doi.org/10.3390/ijms24032849

Ejemplares similares

Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: a comparative study
por: Dömötör, Orsolya, et al.
Publicado: (2019)

Solution speciation and human serum protein binding of indium(III) complexes of 8-hydroxyquinoline, deferiprone and maltol
por: Dömötör, Orsolya, et al.
Publicado: (2022)

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
por: Eloy, Philippine, et al.
Publicado: (2021)

543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
por: Grobler, Jay, et al.
Publicado: (2021)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen
por: Sharaf, Yasmine Ahmed, et al.
Publicado: (2022)

Oxidative DNA Damage by N(4)-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir
por: Kobayashi, Hatasu, et al.
Publicado: (2022)

Novel Polymorph of Favipiravir—An Antiviral Medication
por: Goloveshkin, Alexander S., et al.
Publicado: (2021)

Antiviral efficacy of favipiravir against canine distemper virus infection in vitro
por: Xue, Xianghong, et al.
Publicado: (2019)

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
por: Marlin, Romain, et al.
Publicado: (2022)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
por: Kabinger, Florian, et al.
Publicado: (2021)

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
por: Menéndez-Arias, Luis
Publicado: (2021)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

A sustainable approach for the degradation kinetics study and stability assay of the SARS-CoV-2 oral antiviral drug Molnupiravir
por: Edrees, Fadwa H., et al.
Publicado: (2023)

Antivirals/convalescent-anti-SARS-CoV-2-plasma/imatinib: Haematological disorder and off label use: case report
Publicado: (2021)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
por: Strizki, Julie, et al.
Publicado: (2022)

Highly Antiproliferative Latonduine and Indolo[2,3-c]quinoline Derivatives: Complex Formation with Copper(II) Markedly Changes the Kinase Inhibitory Profile
por: Wittmann, Christopher, et al.
Publicado: (2022)

Solution Equilibrium Studies on Salicylidene Aminoguanidine Schiff Base Metal Complexes: Impact of the Hybridization with L-Proline on Stability, Redox Activity and Cytotoxicity
por: Dömötör, Orsolya, et al.
Publicado: (2022)

Favipiravir – a Modern Antiviral Drug: Synthesis and Modifications
por: Titova, Yulia A., et al.
Publicado: (2020)

Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
por: Mayor, Jennifer, et al.
Publicado: (2021)

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs
por: Mathuber, Marlene, et al.
Publicado: (2020)

8-Hydroxyquinoline-Amino Acid Hybrids and Their Half-Sandwich Rh and Ru Complexes: Synthesis, Anticancer Activities, Solution Chemistry and Interaction with Biomolecules †
por: Pivarcsik, Tamás, et al.
Publicado: (2021)

A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
por: Kulkarni, Prajakta, et al.
Publicado: (2022)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
por: Lee, Ching-Chi, et al.
Publicado: (2021)

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
por: Gordon, Calvin J., et al.
Publicado: (2021)

Molnupiravir for SARS-CoV-2 infection: Public health and policy implications
por: Gray, Edward J., et al.
Publicado: (2023)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
por: Teli, Divya, et al.
Publicado: (2023)

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
por: Painter, Wendy P., et al.
Publicado: (2021)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

Favipiravir elicits antiviral mutagenesis during virus replication in vivo
por: Arias, Armando, et al.
Publicado: (2014)

Favipiravir: A new and emerging antiviral option in COVID-19
por: Agrawal, Umang, et al.
Publicado: (2020)

Potential and action mechanism of favipiravir as an antiviral against Junin virus
por: Zadeh, Vahid Rajabali, et al.
Publicado: (2022)

Favipiravir and Its Structural Analogs: Antiviral Activity and Synthesis Methods
por: Konstantinova, I. D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0hf9of5lgotfh7pvqn6tqp0jbu